Contera Pharma is a Danish biotech company with an affiliate in Seoul, South-Korea developing innovative ASO and siRNA therapeutics to improve life for people suffering from neurological disorders.
Abzu designed active and safe ASO and siRNA therapeutics.
Your partner for precise and exceptional results.
Initially we supported a single researcher with expertise in RNA therapeutics to predict activity for ASO therapeutics. Later, we expanded our partnership to design siRNAs therapeutics and identify novel targets.
A testament to innovation and collaboration.
Abzu’s explainable artificial intelligence technology and in-house RNA and data science capabilities was a key stepping stone for our R&D strategy to develop novel and innovative ASO and siRNA therapeutics.
Kenneth Vielsted Christensen, Chief Scientific Officer
Deepening disease and disease-target understanding.
We accelerated ASO and siRNA therapeutics design through parallel hypotheses testing of targets and individual drug properties.
This approach allows simultaneous exploration of multiple promising avenues — and with an additional understanding of the “why” behind biological mechanisms — is a leap forward in drug discovery.
Abzu multiplies the pace at which potential ASO and siRNA therapeutics can be designed and evaluated, cutting down on both time and financial investment required.
This partnership made headlines.
Abzu
March 22, 2022
Abzu and Contera Pharma expand strategic partnership to add target identification to RNA therapeutic design platform.
Korea IT Times
July 9, 2021
Contera Pharma, a subsidiary of Bukwang Pharm, partners with Abzu to develop new treatment for people suffering from neurological disorders
MedWatch
July 7, 2021
Contera Pharma vil i højere grad rykke forskning internt med nyt samarbejde
Abzu
July 7, 2021
Abzu and Contera Pharma partner to design RNA therapeutics for rare diseases with explainable AI.
Less data, more discovery.
Make the most out of every piece of information.
Contrary to the data-heavy demands of black-box AI, our technology thrives on minimal data. This efficiency not only accelerates the discovery process, but also reduces your barrier to entry to develop new, innovative drugs.
